(Q45917632)

17 December 2017

meta-analysis

0 references

title

Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. (English)

1 reference

17 December 2017

chronic obstructive pulmonary disease

main subject

meta-analysis

0 references

1 reference

1 reference

William L Baker

1

1 reference

17 December 2017

Erica L Baker

series ordinal

2

1 reference

17 December 2017

Craig I Coleman

series ordinal

3

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

17 December 2017

published in

Pharmacotherapy

1 reference

17 December 2017

volume

29

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

891-905

1 reference

17 December 2017

Management of chronic obstructive pulmonary disease

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Contemporary management of chronic obstructive pulmonary disease: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Impact of COPD exacerbations on patient-centered outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

What have we learned from large drug treatment trials in COPD?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The effect of tiotropium on exacerbations and airflow in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Withdrawal from treatment as an outcome in the ISOLDE study of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Toward a consensus definition for COPD exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.891

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.8.891

1 reference

17 December 2017

1 reference

17 December 2017